Menu
Close
Global
×

Company News

Company News
Company News
2026-09-23
ImmuneOnco Reports Breakthrough Phase II Data for IMM0306 in Combination with Lenalidomide: ORR of 92.3% in R/R MZL and 88.6% in R/R FL, Demonstrating a Compelling Efficacy and Safety Profile
The latest data demonstrate that the combination regimen delivers high response rates, durable progression-free survival benefits, and a favorable safety profile in patients with R/R marginal zone lymphoma (MZL) and R/R follicular lymphoma (FL), offering a highly promising new therapeutic option for patients with R/R indolent B-cell lymphomas. The Phase II clinical study is ongoing.
View more
2026-08-27
ImmuneOnco Doses First Patient in Phase II Trial of Palverafusp Alfa (IMM2510) in Combination with Tazlestobart (IMM27M) for First-Line Advanced Hepatocellular Carcinoma
The study is designed to assess the preliminary anti-tumor efficacy and safety of the combination in this patient population.
View more
2026-08-25
ImmuneCare Achieves Dual Milestones for IMC-003 in Clinical Progress: First PAH Patient Dosed, All SAD/MAD Cohorts Completed
These achievements mark significant progress in the program's advancement toward patient validation.
View more
2026-08-22
ImmuneOnco's Amulirafusp Alfa (IMM0306) Receives FDA IND Clearance Phase Ib/II Clinical Trial in Systemic Lupus Erythematosus
This milestone represents a key step forward in the global clinical development of IMM0306 across autoimmune diseases, bringing a potential breakthrough therapeutic option one step closer to millions of SLE patients worldwide.
View more
2026-08-07
ImmuneOnco Subsidiary ImmuneCare Completes Capital Increase of Multi-Million RMB Yuan to Accelerate Non-Oncology Pipeline Development
This capital increase aims to further strengthen ImmuneCare's financial resources and accelerate the research and development of innovative drugs in cardiovascular diseases, such as pulmonary arterial hypertension (PAH), as well as metabolic diseases. This marks the steady implementation of ImmuneOnco's "oncology + non-oncology" dual-engine strategy.
View more
2026-07-27
ImmuneOnco Successfully Convenes Phase II Investigator Meeting of IMC-002 (IMM0306) for Active Systemic Lupus Erythematosus (SLE）
The event aimed to provide a comprehensive overview of the study protocol and unify trial execution standards, laying a solid foundation for the clinical study that is now fully underway.
View more
总计 106 12345678...1718